Question-and-Answer Session
Operator
(Operator Instructions) We'll take our first question from Tycho Peterson JP Morgan.
Tycho Peterson JP Morgan
Kicking off with a question on Dimensions, can you give us a sense as to when you think you will make a go, nogo decision on kind of the next step here and how should we think about this in terms of spending around an additional trial or the clinical generation aspect of it.
Jack Cumming
I will ask Rob if he would answer that.
Robert Cascella
Can you clarify the question a little bit?
Jack Cumming
By the way, it didn't come clear, your voice didn't come clear here. We're checking on our end to see if we have our volume up high enough. So could you just briefly say that again. I apologize to you.
Tycho Peterson JP Morgan
The question is when would you expect to make a go, nogo decision around Dimensions in terms of another study. I am just a little unclear as to what you're thinking about in terms of generating additional clinical data and should we think about follow on trial and what would be the timeline in terms of making a decision there?
Jack Cumming
I am going to let Rob answer that. But it's not necessarily that we're going to generate additional data, that's one of the avenues that we're looking at. But Rob, go ahead.
Robert Cascella
It's really a bit of a multifaceted plan. There is reanalyses of the current data that we intend to present to panel, albeit a delayed panel, and in addition to that, there are different phases of clinical work that we also believe will be necessary in order to reinforce the initial indications, additional indications for use, and obviously be used for reimbursement purposes as well.
It is a multifaceted plan that will take the course of the balance of this year and even into next, but there will be different milestones of accomplishments that will occur over that period of time.
Tycho Peterson JP Morgan
That's helpful. On Cervista, then, I appreciate the color around some of the initial interests. Can you just give us a little bit more color in terms of characterizing these larger laboratories and what is the dialogue about around the fully automated system now, or are you getting a sense that labs are holding off in anticipation or how do we think about the timelines there, too?
- To read the full transcript on Seeking Alpha, click here »
